R. Ravasio, H. Cranmer, I. Kearns, R. Viti, and S. Corinti, “Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor”, AboutOpen, vol. 9, no. 1, pp. 92–104, Oct. 2022.